NEWSLETTER

Sign up to read weekly email newsletter

13 years 🥳 of Publication, 100k+ Stories, 30+ Countries

Legal Desire Media and Insights
Donate
Search
  • Law Firm & In-house Updates
  • Deals
  • Interviews
  • Insight
  • Read to know
  • Courses
Reading: Clifford Chance advises ESTEVE on its binding offer for the acquisition of HRA Pharma Rare Diseases
Share
Aa
Legal Desire Media and InsightsLegal Desire Media and Insights
  • Law Firm & In-house Updates
  • Deals
  • Interviews
  • Insight
  • Read to know
  • Courses
Search
  • Law Firm & In-house Updates
  • Deals
  • Interviews
  • Insight
  • Read to know
  • Courses
Follow US
Legal Desire Media & Insights
Home » Blog » Clifford Chance advises ESTEVE on its binding offer for the acquisition of HRA Pharma Rare Diseases
Deals

Clifford Chance advises ESTEVE on its binding offer for the acquisition of HRA Pharma Rare Diseases

By Nitya Vashishtha 2 Min Read
Share

Clifford Chance has advised global pharmaceutical company ESTEVE on the acquisition from self-care products provider Perrigo Company of HRA Pharma Rare Diseases, a France-based company specialised in rare and ultra-rare diseases.

The proposed acquisition contemplates a total consideration of up to EUR 275 million. Following the information and consultation process with HRA Pharma Works Council in France, Perrigo would be able to exercise the put option granted by ESTEVE and enter into a definitive agreement with ESTEVE for the sale of the Rare Diseases business. The proposed final transaction is expected to close during the third quarter of 2024, subject to the satisfaction of the HRA Works Council consultation and customary closing conditions, including receipt of regulatory approvals.

With this transaction, ESTEVE will increase its portfolio in rare and severe diseases therapeutic area, adding to its current portfolio three new medicines that address Cushing’s syndrome and Adrenocortical Carcinoma (Metopirone, Lysodren, and Ketoconazole HRA). The transaction represents a further step on ESTEVE’s international path and aim to cover unmet patient’s needs, including effective options for the long-term management of Cushing’s syndrome and Adrenocortical Carcinoma diseases.

The Clifford Chance core-team advising ESTEVE was led by Corporate / M&A partner Guillermo Guardia, together with senior associate José María Vilaseca and associates Estel Casas, María Viñas and Alex Jori. Counsels Fernando Escribano and Jorge Martín-Fernández advised on tax and employment-related matters. The wider Clifford Chance team consisted of lawyers in 11 Clifford Chance offices including partners Marianne Pezant (Paris), Thomas Krecek (Frankfurt), Gareth Camp (London), Thais García (New York), Umberto Penco Salvi (Milan) and Niek de Pauw (Brussels).

You Might Also Like

Freshfields advises Charterhouse on the entry of new investors in Novétude

Mayer Brown advises Vitruvian Partners on acquisition of premium travel business Great Rail Journeys

Mayer Brown advises OQ Trading on 15-year LNG Sale and Purchase Agreement with LNG Alliance relating to the Amigo LNG Project

Linklaters Zhao Sheng advises UBS AG on the acquisition of full ownership of UBS Securities in China

Hogan Lovells advises Hayfin Capital on minority investment in Novétude Group

Subscribe

Subscribe to our newsletter to get our newest articles instantly!

Don’t miss out on new posts, Subscribe to newsletter Get our latest posts and announcements in your inbox.

Sign Up For Daily Newsletter

Be keep up! Get the latest breaking news delivered straight to your inbox.

Don’t miss out on new posts, Subscribe to newsletter Get our latest posts and announcements in your inbox.

By signing up, you agree to our Terms of Use and acknowledge the data practices in our Privacy Policy. You may unsubscribe at any time.
Nitya Vashishtha April 30, 2024
Share this Article
Facebook Twitter Email Copy Link Print

YOU MAY ALSO LIKE

Freshfields advises Charterhouse on the entry of new investors in Novétude

Freshfields advised Charterhouse Capital Partners (“Charterhouse”), one of the longest-established private equity firms operating in Europe, on the transaction involving…

Deals
May 19, 2025

Mayer Brown advises Vitruvian Partners on acquisition of premium travel business Great Rail Journeys

London – Mayer Brown has advised private equity firm Vitruvian Partners on its acquisition of rail specialist tour operator Great…

Deals
May 19, 2025

Mayer Brown advises OQ Trading on 15-year LNG Sale and Purchase Agreement with LNG Alliance relating to the Amigo LNG Project

Singapore – Mayer Brown advised OQ Trading (OQT) on its 15-year LNG sale and purchase agreement (SPA) with LNG Alliance…

Deals
May 19, 2025

Linklaters Zhao Sheng advises UBS AG on the acquisition of full ownership of UBS Securities in China

Linklaters and its China joint operation partner Zhao Sheng Law Firm (Zhao Sheng) acted as joint legal advisors to UBS…

Deals
May 19, 2025

For over 10 years, Legal Desire provides credible legal industry updates and insights across the globe.

  • About
  • Contact Us
  • Legal Marketing Service for Law Firms and Lawyers
  • Privacy Policy
  • Terms & Condition
  • Cancellation/Refund Policy

Follow US: 

Legal Desire Media & Insights

For Submissions/feedbacks/sponsorships/advertisement/syndication: office@legaldesire.com

Legal Desire Media & Insights 2023

✖
Cleantalk Pixel

Removed from reading list

Undo
Welcome Back!

Sign in to your account

Lost your password?